• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
MENUMENU
MENUMENU
  • Home
  • About
    • Contact Us
    • FlaglerLive Board of Directors
    • Comment Policy
    • Mission Statement
    • Our Values
  • Live Calendar
  • Submit Obituary
  • Submit an Event
  • Support FlaglerLive
  • Advertise on FlaglerLive (386) 503-3808
  • Search Results

FlaglerLive

No Bull, no Fluff, No Smudges

MENUMENU
  • Flagler
    • Flagler County Commission
    • Beverly Beach
    • Economic Development Council
    • Flagler History
    • Mondex/Daytona North
    • The Hammock
    • Tourist Development Council
  • Palm Coast
    • Palm Coast City Council
    • Palm Coast Crime
  • Bunnell
    • Bunnell City Commission
    • Bunnell Crime
  • Flagler Beach
    • Flagler Beach City Commission
    • Flagler Beach Crime
  • Cops/Courts
    • Circuit & County Court
    • Florida Supreme Court
    • Federal Courts
    • Flagler 911
    • Fire House
    • Flagler County Sheriff
    • Flagler Jail Bookings
    • Traffic Accidents
  • Rights & Liberties
    • Fourth Amendment
    • First Amendment
    • Privacy
    • Second Amendment
    • Seventh Amendment
    • Sixth Amendment
    • Sunshine Law
    • Third Amendment
    • Religion & Beliefs
    • Human Rights
    • Immigration
    • Labor Rights
    • 14th Amendment
    • Civil Rights
  • Schools
    • Adult Education
    • Belle Terre Elementary
    • Buddy Taylor Middle
    • Bunnell Elementary
    • Charter Schools
    • Daytona State College
    • Flagler County School Board
    • Flagler Palm Coast High School
    • Higher Education
    • Imagine School
    • Indian Trails Middle
    • Matanzas High School
    • Old Kings Elementary
    • Rymfire Elementary
    • Stetson University
    • Wadsworth Elementary
    • University of Florida/Florida State
  • Economy
    • Jobs & Unemployment
    • Business & Economy
    • Development & Sprawl
    • Leisure & Tourism
    • Local Business
    • Local Media
    • Real Estate & Development
    • Taxes
  • Commentary
    • The Conversation
    • Pierre Tristam
    • Diane Roberts
    • Guest Columns
    • Byblos
    • Editor's Blog
  • Culture
    • African American Cultural Society
    • Arts in Palm Coast & Flagler
    • Books
    • City Repertory Theatre
    • Flagler Auditorium
    • Flagler Playhouse
    • Flagler Youth Orchestra
    • Jacksonville Symphony Orchestra
    • Palm Coast Arts Foundation
    • Special Events
  • Elections 2022
    • Amendments and Referendums
    • Presidential Election
    • Campaign Finance
    • City Elections
    • Congressional
    • Constitutionals
    • Courts
    • Governor
    • Polls
    • Voting Rights
  • Florida
    • Federal Politics
    • Florida History
    • Florida Legislature
    • Florida Legislature
    • Ron DeSantis
  • Health & Society
    • Flagler County Health Department
    • Ask the Doctor Column
    • Health Care
    • Health Care Business
    • Covid-19
    • Children and Families
    • Medicaid and Medicare
    • Mental Health
    • Poverty
    • Violence
  • All Else
    • Daily Briefing
    • Americana
    • Obituaries
    • News Briefs
    • Weather and Climate
    • Wildlife

Experimental Alzheimer’s Drug’s Promise and Problems

December 3, 2022 | FlaglerLive | 1 Comment

alzheimer's drug results
Fuzzy results. (Florey Institute)

By Ritchie Williamson and Stuart Dickens

The first drug that can slow the rate of decline in Alzheimer’s patients has been found. The experimental drug, called lecanemab, is an antibody that targets the toxic clumps of amyloid protein associated with the mind-robbing disease. While these results are cause for celebration, there are still significant questions about its safety and rollout.




The full results of the phase 3 lecanemab drug trial (the final stage of testing in humans) have been published in the New England Journal of Medicine. The trial showed that patients receiving the drug had a 27% slower disease progression than those receiving a placebo after 18 months of treatment.

Overall, this is good news. For the first time, we have a potential treatment that has a demonstrated effect on both the symptoms and underlying pathology of Alzheimer’s disease. These results are a breakthrough in the search for treatments for this devastating disease and give a strong indication that the course of the disease can be altered.

But the results paint a mixed picture for those with Alzheimer’s. On one hand, this is the first drug that has been shown to have any effect on slowing the progression of the disease. On the other hand, the apparent effects are slight and the risks are not inconsiderable.

About 1,800 people with early-stage Alzheimer’s took part in the global trial. The participants were randomly assigned to receive either lecanemab or placebo intravenously every two weeks. The study was “double blind”, meaning neither the participants nor the researchers knew who was receiving the experimental drug and who was receiving the placebo until the end of the trial.




Throughout the study, the participants’ disease progression was tracked using the clinical dementia rating scale, which scores the patient on cognition and ability to live independently. The participants’ brains were also scanned for the two proteins commonly associated with Alzheimer’s disease: amyloid and tau.

Alzheimer’s scores in both groups worsened during the 18 months of the study, but the rate of decline was slower in those receiving the lecanemab. Also, the magnitude of the slowing, while statistically significant (not likely to be due to chance) was small – a 0.45 reduction on an 18-point scale.

Some experts are concerned that this effect may not be clinically meaningful. In a statement to the Science Media Centre, Rob Howard, professor of old age psychiatry at UCL, said that “none of the reported results, including the primary outcome, reached accepted levels of improvement to constitute a clinically meaningful treatment effect”.

The success of lecanemab was also measured by the amount of amyloid and tau protein in those on the experimental drug compared with those receiving the placebo infusion. The results showed a reduction in these proteins in those receiving lecanemab.

Indeed, the levels of brain amyloid were reduced to below the threshold needed for a positive Alzheimer’s diagnosis. However, markers of brain cell death were unaffected, indicating that amyloid in Alzheimer’s disease is just one mechanism in a complicated disease landscape.

Side-effects

About one in four participants (26.6%) in the lecanemab group experienced brain swelling or a bleed on the brain (which can be both minor or major). STAT, a medical news website, reported that a man died of a brain haemorrhage after receiving lecanemab, citing a possible interaction with his blood thinning medication.

A short while later, the journal Science reported a second death of a trial patient, also after receiving treatment for a stroke. However, the drug’s developer, Eisa, told Science: “All the available safety information indicates that lecanemab therapy is not associated with an increased risk of death overall or from any specific cause.”

Nevertheless, given the possibility that patients may be on the drug for the rest of their lives, more research is needed on safety and interactions with existing medications.




It’s also important to find out how long-lived the improvements in cognition are, and whether the drug continues to slow the rate of decline, or if the results plateau – or even decline.

It should be noted that only patients who had a sufficient level of amyloid detected in the brain or spinal fluid – which requires a PET brain scan or an invasive lumbar puncture – were eligible to take part in this phase 3 trial. In the UK, Alzheimer’s is currently diagnosed via an interview with a doctor. Dr Susan Kohlhaas, director of research at Alzheimer’s Research UK, says the NHS is not ready for a new era of dementia treatment.

We estimate that unless there are drastic changes in how people access specialist diagnostic tests for Alzheimer’s disease, only 2% of people eligible for drugs like lecanemab will be able to access them.

Restructuring NHS dementia services to provide routine and timely PET scans or lumbar punctures would be a costly and lengthy process.

Based on previous results, Eisai applied to the US drug regulator (the Food and Drug Administration) for accelerated approval of their drug. A decision is expected by January 6 2023. If accelerated approval is granted by the regulator, these latest results will probably support an application for full approval.

Ritchie Williamson is Director of research and Associate Professor in Therapeutics at the University of Bradford. Stuart Dickens
is a Post Doctoral Research Assistant at the University of Bradford, Britain.


The Conversation arose out of deep-seated concerns for the fading quality of our public discourse and recognition of the vital role that academic experts could play in the public arena. Information has always been essential to democracy. It’s a societal good, like clean water. But many now find it difficult to put their trust in the media and experts who have spent years researching a topic. Instead, they listen to those who have the loudest voices. Those uninformed views are amplified by social media networks that reward those who spark outrage instead of insight or thoughtful discussion. The Conversation seeks to be part of the solution to this problem, to raise up the voices of true experts and to make their knowledge available to everyone. The Conversation publishes nightly at 9 p.m. on FlaglerLive.

Previous Conversations:

  • Understanding the Heat Dome: Why America Is Baking
  • Endorsements Aren’t As Influential as You Think
  • Wiccan Celebrations and the Permanence of Change
  • Privacy Isn’t In the Constitution. But It’s Everywhere in Constitutional Law.
  • Anti-Trans Legislation and Lawsuits Are Pushing back Against Chosen Pronouns
  • How Mike Pence’s Unremarkable Actions on Jan. 6 Saved the Nation
  • Blaspheming Human Rights: The Hypocrisy at the Core of Authoritarian Muslim Nations
  • There Is No One ‘Religious View’ on Abortion
  • Inflation Is Spiking. Can the Fed Raise Interest Rates Without Spiking Unemployment, Too?
  • Blaming ‘Evil’ Is Not Enough
  • Did the 1994 Assault Weapons Ban Diminish Mass Shootings? Yes.
  • Crowded Primaries Are Good for Extremists, Bad for Voters
  • To Get Safe Schools, Mental Health Resources Are Critical
  • Antarctica’s Riskiest Glacier Is Losing Its Grip
  • The Legal Age to Buy Assault Weapons Doesn’t Make Sense

See the Full Conversation Archives
Print Friendly, PDF & Email
You and your neighbors collectively read our articles about 25,000 times each day (that's not a typo) with up to 65,000 daily reads during emergencies like hurricanes. Flagler County residents rely on FlaglerLive for essential, bold and analytical journalism that cannot be found anywhere else. But we depend on your support. Please join our December fund drive! If you donate the cost of a scoop of ice cream, you will be helping us continue to provide comprehensive local news and honest, serious journalism for our community. If you can donate more or become a monthly donor, even better. Donations are tax deductible since FlaglerLive is a 501(c)(3) non-profit news organization. Donate by clicking anywhere in this box. Think of it as buying a scoop, in every sense of the term!  
All donors' identities are kept confidential and anonymous.
   

Reader Interactions

  • politis matovina attorneys for justice personal injury law auto truck accidents
  • grand living realty

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Advertisers

  • grand living realty
  • politis matovina attorneys for justice personal injury law auto truck accidents

Recent Comments

  • Pierre Tristam on The Hung Jury Got It Right in the Monserrate Teron Trial
  • blerbfamilyfive on Why Will Furry Is Demolishing the Flagler Youth Orchestra
  • We believe the girl on The Hung Jury Got It Right in the Monserrate Teron Trial
  • DAVE on Flagler Pride Fest Is On Despite Hostile Climate, Drag Show Included, With a Few Cautionary Tucks
  • Blame Game on No, Flagler Beach Isn’t Asking for Money. It’s Asking for Cooperation from County and Cities.
  • Laurel on Behind the Divorce, a Bitter, Threat-Ridden Clash Between Waste Pro and Palm Coast Over Recycling Bins
  • Deborah Coffey on Wadsworth Elementary’s Paul Peacock Is Told He’s Done in Flagler Schools; New Principal To Be Named Later
  • Flatsflyer on Wadsworth Elementary’s Paul Peacock Is Told He’s Done in Flagler Schools; New Principal To Be Named Later
  • Greg on No, Flagler Beach Isn’t Asking for Money. It’s Asking for Cooperation from County and Cities.
  • Bailey’s Mom on Wadsworth Elementary’s Paul Peacock Is Told He’s Done in Flagler Schools; New Principal To Be Named Later
  • jake on Flagler Pride Fest Is On Despite Hostile Climate, Drag Show Included, With a Few Cautionary Tucks
  • Dennis Clark on No, Flagler Beach Isn’t Asking for Money. It’s Asking for Cooperation from County and Cities.
  • Bryan on “A Fitting Conclusion”: Family Speaks of Pilot Ray Miller’s Life of Adventure Before Crash
  • Ray W. on The Hung Jury Got It Right in the Monserrate Teron Trial
  • Ray W. on The Hung Jury Got It Right in the Monserrate Teron Trial
  • Dee on Wadsworth Elementary’s Paul Peacock Is Told He’s Done in Flagler Schools; New Principal To Be Named Later

Log in